journal article·2024-09-11

Extracellular Vesicles Comprising Carborane Prepared by a Host Exchanging Reaction as a Boron Carrier for Boron Neutron Capture Therapy

Riku Kawasaki, Ayano Oshige, Nanami Kono, Keita Yamana, Hidetoshi Hirano, Yamato Miura, Ryuji Yorioka, Kaori Bando, Anri Tabata, Naoki Yasukawa, Masahiro Sadakane, Yu Sanada, Minoru Suzuki, Takushi Takata, Yoshinori Sakurai, Hiroki Tanaka, Dilimulati Yimiti, Shigeru Miyaki, Nobuo Adachi, Ryosuke Mizuta, Yoshihiro Sasaki, Kazunari Akiyoshi, Yoshihide Hattori, Mitsunori Kirihata, Takeshi Nagasaki, Atsushi Ikeda

ACS Applied Materials & Interfaces· Volume 16· Issue 36
Publisher page

Abstract

With their low immunogenicity and excellent deliverability, extracellular vesicles (EVs) are promising platforms for drug delivery systems. In this study, hydrophobic molecule loading techniques were developed via an exchange reaction based on supramolecular chemistry without using organic solvents that can induce EV disruption and harmful side effects. To demonstrate the availability of an exchanging reaction to prepare drug-loading EVs, hydrophobic boron cluster carborane (CB) was introduced to EVs (CB@EVs), which is expected as a boron agent for boron neutron capture therapy (BNCT). The exchange reaction enabled the encapsulation of CB to EVs without disrupting their structure and forming aggregates. Single-particle analysis revealed that an exchanging reaction can uniformly introduce cargo molecules to EVs, which is advantageous in formulating pharmaceuticals. The performance of CB@EVs as boron agents for BNCT was demonstrated in vitro and in vivo. Compared to L-BPA, a clinically available boron agent, and CB delivered with liposomes, CB@EV systems exhibited the highest BNCT activity in vitro due to their excellent deliverability of cargo molecules via an endocytosis-independent pathway. The system can deeply penetrate 3D cultured spheroids even in the presence of extracellular matrices. The EV-based system could efficiently accumulate in tumor tissues in tumor xenograft model mice with high selectivity, mainly via the enhanced permeation and retention effect, and the deliverability of cargo molecules to tumor tissues in vivo enhanced the therapeutic benefits of BNCT compared to the L-BPA/fructose complex. All of the features of EVs are also advantageous in establishing anticancer agent delivery platforms.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Boron Compounds in Chemistry · Extracellular vesicles in disease · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Applied Chemistry Program, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima 739-8527, Japan

Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka 558-8585, Japan

Institute for Integrated Radiation and Nuclear Science, Kyoto University, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan

Department of Orthopedic Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan

Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Kyoto Daigaku Katsura, Nishikyo-ku, Kyoto 615-8510, Japan

Department of Molecular Medicine, Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

Research Center for BNCT, Osaka Metropolitan University, 1-2, Gakuen-cho, Naka-ku Sakai, Osaka 599-8531, Japan

Funding

ACT-X · Japan Society for the Promotion of Science

References (100+)

Show source-provided references
1. 10.1007/s10787-022-01115-710.1007/s10787-022-01115-7 ↗
2. 10.1016/j.lfs.2019.11673310.1016/j.lfs.2019.116733 ↗
3. 10.1007/s10620-020-06262-x10.1007/s10620-020-06262-x ↗
4. 10.1016/j.impact.2020.10026110.1016/j.impact.2020.100261 ↗
5. 10.1016/j.actbio.2019.05.05410.1016/j.actbio.2019.05.054 ↗
6. 10.3389/fcell.2021.75107910.3389/fcell.2021.751079 ↗
7. 10.3389/fbioe.2022.93944110.3389/fbioe.2022.939441 ↗
8. 10.1038/s41596-019-0245-410.1038/s41596-019-0245-4 ↗
9. 10.1111/cpr.1285710.1111/cpr.12857 ↗
10. 10.1016/j.canlet.2020.05.00410.1016/j.canlet.2020.05.004 ↗
11. 10.1016/j.semcancer.2022.02.02010.1016/j.semcancer.2022.02.020 ↗
12. 10.3390/ijms2118664610.3390/ijms21186646 ↗
13. 10.1016/j.jddst.2021.10257710.1016/j.jddst.2021.102577 ↗
14. 10.1016/j.vesic.2023.10002310.1016/j.vesic.2023.100023 ↗
15. 10.3390/nano1106148110.3390/nano11061481 ↗
16. 10.1016/j.jconrel.2020.10.02010.1016/j.jconrel.2020.10.020 ↗
17. 10.1038/oncsis.2016.5210.1038/oncsis.2016.52 ↗
18. 10.1016/j.jconrel.2022.05.02710.1016/j.jconrel.2022.05.027 ↗
19. 10.2147/ijn.s26449810.2147/ijn.s264498 ↗
20. 10.1016/j.nano.2017.03.00110.1016/j.nano.2017.03.001 ↗
21. 10.3390/pharmaceutics1501006610.3390/pharmaceutics15010066 ↗
22. 10.3390/pharmaceutics1004021810.3390/pharmaceutics10040218 ↗
23. 10.1021/acsbiomaterials.9b0041710.1021/acsbiomaterials.9b00417 ↗
24. 10.1007/s11095-022-03224-y10.1007/s11095-022-03224-y ↗
25. 10.1016/j.jconrel.2022.06.02610.1016/j.jconrel.2022.06.026 ↗
26. 10.1371/journal.pone.021454510.1371/journal.pone.0214545 ↗
27. 10.1186/s13045-021-01141-y10.1186/s13045-021-01141-y ↗
28. 10.1016/j.lfs.2020.11836910.1016/j.lfs.2020.118369 ↗
29. 10.1021/acs.bioconjchem.9b0008510.1021/acs.bioconjchem.9b00085 ↗
30. 10.1016/j.biotechadv.2012.08.00810.1016/j.biotechadv.2012.08.008 ↗
31. 10.1016/j.addr.2012.08.00810.1016/j.addr.2012.08.008 ↗
32. 10.1016/j.biomaterials.2022.12194910.1016/j.biomaterials.2022.121949 ↗
33. 10.3390/ijms2205266610.3390/ijms22052666 ↗
34. 10.1021/acsami.0c1045810.1021/acsami.0c10458 ↗
35. 10.1016/j.actbio.2023.02.01810.1016/j.actbio.2023.02.018 ↗
36. 10.1016/j.actbio.2020.06.03610.1016/j.actbio.2020.06.036 ↗
37. 10.1016/j.jjcc.2017.03.00510.1016/j.jjcc.2017.03.005 ↗
38. 10.1016/j.jconrel.2021.05.03210.1016/j.jconrel.2021.05.032 ↗
39. 10.1016/j.ijbiomac.2021.06.01010.1016/j.ijbiomac.2021.06.010 ↗
40. 10.1016/j.jddst.2022.10403210.1016/j.jddst.2022.104032 ↗
41. 10.1007/s00289-023-04759-910.1007/s00289-023-04759-9 ↗
42. 10.1016/j.drudis.2021.10.00710.1016/j.drudis.2021.10.007 ↗
43. 10.1186/s12951-023-01973-510.1186/s12951-023-01973-5 ↗
44. 10.1186/s13578-021-00650-010.1186/s13578-021-00650-0 ↗
45. 10.1016/j.jconrel.2020.07.04210.1016/j.jconrel.2020.07.042 ↗
46. 10.3390/molecules2604113510.3390/molecules26041135 ↗
47. 10.3390/cancers1315370010.3390/cancers13153700 ↗
48. 10.1023/A:100756523013010.1023/A:1007565230130 ↗
49. 10.1023/A:101605131681510.1023/A:1016051316815 ↗
50. 10.1039/D0NA00132E10.1039/D0NA00132E ↗
51. 10.1039/D3OB00027C10.1039/D3OB00027C ↗
52. 10.1002/chem.20180365710.1002/chem.201803657 ↗
53. 10.1002/cmdc.20220007010.1002/cmdc.202200070 ↗
54. 10.1002/chem.20230138510.1002/chem.202301385 ↗
55. 10.1039/d0cc06557a10.1039/d0cc06557a ↗
56. 10.1039/d0py00710b10.1039/d0py00710b ↗
57. 10.1039/d3na00028a10.1039/d3na00028a ↗
58. 10.1039/D2NA00839D10.1039/D2NA00839D ↗
59. 10.1158/1078-0432.CCR-05-003510.1158/1078-0432.CCR-05-0035 ↗
60. 10.1039/D3NR01667F10.1039/D3NR01667F ↗
61. 10.1039/d2ob00764a10.1039/d2ob00764a ↗
62. 10.1186/s12951-022-01304-010.1186/s12951-022-01304-0 ↗
63. 10.1039/C9CC03924D10.1039/C9CC03924D ↗
64. 10.3389/fmed.2023.119988110.3389/fmed.2023.1199881 ↗
65. 10.1016/j.bbrc.2019.11.14410.1016/j.bbrc.2019.11.144 ↗
66. 10.3390/cells1012342110.3390/cells10123421 ↗
67. 10.1038/s41467-022-29780-w10.1038/s41467-022-29780-w ↗
68. 10.1039/D0PY00710B10.1039/D0PY00710B ↗
69. 10.1021/acs.bioconjchem.6b0045410.1021/acs.bioconjchem.6b00454 ↗
70. 10.1021/mp400641u10.1021/mp400641u ↗
71. 10.2147/IJN.S20355510.2147/IJN.S203555 ↗
72. 10.1248/cpb.c19-0097110.1248/cpb.c19-00971 ↗
73. 10.1016/j.nano.2023.10265910.1016/j.nano.2023.102659 ↗
74. 10.1016/j.molliq.2021.11636710.1016/j.molliq.2021.116367 ↗
75. 10.1016/j.ijpx.2022.10013410.1016/j.ijpx.2022.100134 ↗
76. 10.3390/molecules2419360910.3390/molecules24193609 ↗
77. 10.1021/acs.langmuir.1c0250610.1021/acs.langmuir.1c02506 ↗
78. 10.1021/acs.molpharmaceut.1c0088210.1021/acs.molpharmaceut.1c00882 ↗
79. 10.1002/adfm.20210096910.1002/adfm.202100969 ↗
80. 10.1021/acs.molpharmaceut.2c0077110.1021/acs.molpharmaceut.2c00771 ↗
81. 10.1016/j.canlet.2015.10.02010.1016/j.canlet.2015.10.020 ↗
82. 10.1186/s12951-022-01496-510.1186/s12951-022-01496-5 ↗
83. 10.3389/fsufs.2019.0002310.3389/fsufs.2019.00023 ↗
84. 10.1021/acsami.3c0044610.1021/acsami.3c00446 ↗
85. 10.1039/D2FO02013K10.1039/D2FO02013K ↗
86. 10.1016/j.bbrc.2021.10.06310.1016/j.bbrc.2021.10.063 ↗
87. 10.7567/JJAP.53.06JL0110.7567/JJAP.53.06JL01 ↗
88. 10.3390/v1210111710.3390/v12101117 ↗
89. 10.3390/ijms24121019410.3390/ijms241210194 ↗
90. 10.1002/mabi.20220046210.1002/mabi.202200462 ↗
91. 10.1002/cmdc.20200065610.1002/cmdc.202000656 ↗
92. 10.1039/D0OB01379J10.1039/D0OB01379J ↗
93. 10.1021/acsabm.0c0021110.1021/acsabm.0c00211 ↗
94. 10.1002/cptc.20200002210.1002/cptc.202000022 ↗
95. 10.1002/chem.20220307110.1002/chem.202203071 ↗
96. 10.1016/j.jaci.2020.02.03210.1016/j.jaci.2020.02.032 ↗
97. 10.1039/C4RA08011D10.1039/C4RA08011D ↗
98. 10.3402/jev.v3.2464110.3402/jev.v3.24641 ↗
99. 10.1074/jbc.m114.58804610.1074/jbc.m114.588046 ↗
100. 10.1016/j.addr.2022.11432410.1016/j.addr.2022.114324 ↗